Aarti Drugs Limited (AARTIDRUGS.BO)
INR 330.65
(2.85%)
INR 330.65
(2.85%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.75 Billion INR | 34.25% |
| 2022 | 2.05 Billion INR | 46.09% |
| 2021 | 1.4 Billion INR | -7.12% |
| 2020 | 1.51 Billion INR | -18.82% |
| 2019 | 1.86 Billion INR | -10.58% |
| 2018 | 2.08 Billion INR | 2.72% |
| 2017 | 2.02 Billion INR | 0.57% |
| 2016 | 2.01 Billion INR | 5.39% |
| 2015 | 1.91 Billion INR | 16.98% |
| 2014 | 1.63 Billion INR | 113.3% |
| 2013 | 766.42 Million INR | -5.03% |
| 2012 | 807.04 Million INR | 20.59% |
| 2011 | 669.23 Million INR | -74.98% |
| 2010 | 2.67 Billion INR | 41.66% |
| 2009 | 1.88 Billion INR | -1.76% |
| 2008 | 1.92 Billion INR | -11.48% |
| 2007 | 2.17 Billion INR | 9.02% |
| 2006 | 1.99 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.88 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 2.75 Billion INR | 0.0% |
| 2023 FY | 2.75 Billion INR | 34.25% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 2.12 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 1.37 Billion INR | 0.0% |
| 2022 FY | 2.05 Billion INR | 46.09% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 2.05 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 1.31 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 1.4 Billion INR | 0.0% |
| 2021 FY | 1.4 Billion INR | -7.12% |
| 2020 Q2 | 1.57 Billion INR | 0.0% |
| 2020 Q4 | 1.51 Billion INR | 0.0% |
| 2020 FY | 1.51 Billion INR | -18.82% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q4 | 1.86 Billion INR | 0.0% |
| 2019 Q2 | 1.98 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 1.86 Billion INR | -10.58% |
| 2018 Q4 | 2.08 Billion INR | 0.0% |
| 2018 Q2 | 1.98 Billion INR | 0.0% |
| 2018 FY | 2.08 Billion INR | 2.72% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q2 | 1.92 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 2.02 Billion INR | 0.57% |
| 2017 Q4 | 2.02 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 2.01 Billion INR | 5.39% |
| 2016 Q4 | 2.01 Billion INR | 0.0% |
| 2016 Q2 | 1.91 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q4 | 1.91 Billion INR | 0.0% |
| 2015 FY | 1.91 Billion INR | 16.98% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 1.71 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 656 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 1.63 Billion INR | 0.0% |
| 2014 FY | 1.63 Billion INR | 113.3% |
| 2013 FY | 766.42 Million INR | -5.03% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 766.42 Million INR | 0.0% |
| 2013 Q2 | 789.2 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q2 | 1.19 Billion INR | 0.0% |
| 2012 FY | 807.04 Million INR | 20.59% |
| 2012 Q4 | 807.04 Million INR | 0.0% |
| 2011 FY | 669.23 Million INR | -74.98% |
| 2010 FY | 2.67 Billion INR | 41.66% |
| 2009 FY | 1.88 Billion INR | -1.76% |
| 2008 FY | 1.92 Billion INR | -11.48% |
| 2007 FY | 2.17 Billion INR | 9.02% |
| 2006 FY | 1.99 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | -337.866% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 87.103% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -1765.253% |
| Granules India Limited | 689.71 Million INR | -299.197% |
| Indoco Remedies Limited | 3.51 Billion INR | 21.721% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | -1070.621% |
| Alkem Laboratories Limited | 400 Million INR | -588.325% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -77131.417% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -9791.148% |
| Bajaj HealthCare Limited | 650.34 Million INR | -323.36% |
| Bliss GVS Pharma Limited | 355.92 Million INR | -673.568% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 54.035% |
| Eris Lifesciences Limited | 6.54 Billion INR | 57.933% |
| FDC Limited | 2.46 Million INR | -111550.446% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | -81.507% |
| Gufic Biosciences Limited | 1.53 Billion INR | -78.829% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -2366.54% |
| Ipca Laboratories Limited | 5.8 Billion INR | 52.563% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -3543.377% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | -50.044% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 67.999% |
| Lupin Limited | 1.55 Billion INR | -77.312% |
| Mankind Pharma Limited | 248.67 Million INR | -1007.179% |
| Medicamen Biotech Limited | 12.55 Million INR | -21829.908% |
| Medico Remedies Limited | 8.67 Million INR | -31649.308% |
| Megasoft Limited | 1.35 Billion INR | -102.886% |
| NATCO Pharma Limited | 53 Million INR | -5094.906% |
| Piramal Pharma Limited | 24.83 Billion INR | 88.915% |
| RPG Life Sciences Limited | -30.3 Million INR | 9186.799% |
| Sigachi Industries Limited | 265.79 Million INR | -935.862% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -20601.504% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -1196.549% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 225965.463% |
| Unichem Laboratories Limited | 382.22 Million INR | -620.342% |
| Wanbury Limited | 820 Million INR | -235.768% |
| Windlas Biotech Limited | 20.18 Million INR | -13543.707% |
| ZIM Laboratories Limited | 356 Million INR | -673.386% |
| Zydus Lifesciences Limited | 251 Million INR | -996.932% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -2482.833% |
| Divi's Laboratories Limited | 20 Million INR | -13666.5% |
| Hester Biosciences Limited | 1.81 Billion INR | -51.469% |
| Procter & Gamble Health Limited | 68.8 Million INR | -3901.89% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -19611.483% |
| Bal Pharma Limited | 363.82 Million INR | -656.767% |
| Strides Pharma Science Limited | 6.71 Billion INR | 58.998% |
| Venus Remedies Limited | 386.8 Million INR | -611.815% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -688225.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | -96.232% |
| Shilpa Medicare Limited | 5.6 Billion INR | 50.848% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 72.726% |
| Valiant Laboratories Limited | 746.63 Million INR | -268.764% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -1064.679% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | -160.163% |
| Themis Medicare Limited | 267.74 Million INR | -928.348% |
| Hikal Limited | 4.22 Billion INR | 34.887% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 82.835% |
| Sequent Scientific Limited | 1.42 Billion INR | -92.918% |
| Novartis India Limited | 50.7 Million INR | -5330.572% |
| Wockhardt Limited | 8.91 Billion INR | 69.099% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 91.307% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | -512.926% |
| Morepen Laboratories Limited | 33.64 Million INR | -8084.602% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -1961.764% |